Randomised trial of mefenamic acid versus tranexamic acid in management of menorrhagia

Madhu J.1*, Shylaja A. S.2

1Department of Obstetrics and Gynecology, Karnataka Institute of Medical Sciences, Hubli, Karnataka, India
2Department of Obstetrics and Gynecology, St. Philomena’s Hospital, Viveknagar, Bengaluru, Karnataka, India

Received: 09 August 2017
Accepted: 04 September 2017

*Correspondence:
Dr. Madhu J.
E-mail: madhuobg@yahoo.co.in

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: The objective of the study was to compare the efficacy of mefenamic acid, a non-inflammatory drug with tranexamic acid, an antifibrinolytic drug in management of menorrhagia.

Methods: Randomised trial of women attending outpatient department of St. Philomena’s hospital, Bangalore with complaints of menorrhagia. Fifty four patients with complaints of menorrhagia were randomly assigned to receive either mefenamic acid 500 mg tid (group A- 24 patients) or tranexamic acid 1 gm TID (group B- 26 patients) from day one to day five for three consecutive menstrual cycles.

Results: Reduction in menstrual blood loss as assessed by pictorial blood loss assessment chart was more in group B (50%) than in Group A (30%) (ANOVA, covariates with F=59.647, p<0.001). Difference in improvement of dysmenorrhoea was not statistically significant (p=0.640). Side effects were less in group B compared to group A (p=0.271). Post treatment Hb% significantly improved in both groups (p=0.015 in group A, p<0.001 in gr B). Acceptability was statistically similar in both groups (p>0.05).

Conclusions: Both mefenamic acid and tranexamic acid were effective in management of menorrhagia. Tranexamic acid was significantly superior to mefenamic acid in terms of reduction in menstrual blood loss.

Keywords: Menorrhagia, Mefenamic acid, Pictoral blood loss assessment chart, Tranexamic acid

INTRODUCTION

Menorrhagia is an important healthcare problem in women. Menorrhagia is regular but heavy menstrual bleeding objectively defined as menstrual blood loss more than 80 ml. Objective assessment of menstrual blood loss by alkaline haematin method is the best method available for menstrual blood loss. But it uses specialised and time consuming techniques which are not available for routine clinical use. In an attempt to create a more accurate, yet simple method of assessment, a pictorial blood loss assessment chart (PBAC) was devised by Higgham et al which corresponds well with objective measurement of blood loss which was easy to use and has a role in monitoring the treatment of menorrhagia. Pictoral score of 100 or more when used as a diagnostic test for menorrhagia was found to have a specificity and sensitivity of more than 80%.1-3 Once a baseline score has been established, subsequent treatment cycles are being assessed in same way and effectiveness assessed by a decreasing score. Studies using PBAC score for monitoring treatment of menorrhagia has been reported.4,5

Mechanism controlling menstrual bleeding is poorly understood. Heavy but regular menstrual bleeding can be encountered in ovulating women. In the absence of specific pathological cause, it is presumed that this reflects subtle disturbances in endometrial tissue mechanism. In the past decade, studies have shown increased endometrial fibrinolysis and an alteration in
prostaglandin balance as local uterine abnormalities causing menorrhagia. These observations provide the rationale basis of treatment. Tranexamic acid is most commonly used antifibrinolytic drug and mefenamic acid is most commonly used non-steroidal anti-inflammatory drug (NSAID) used in management of menorrhagia.7,8

This study was conducted to compare the efficacy of mefenamic acid, an NSAID and tranexamic acid, an antifibrinolytic agent in the management of menorrhagia.

METHODS

One year study of women attending outpatient department of St. Philomena’s Hospital, Bangalore with complaints of menorrhagia was conducted.

Inclusion criteria

Patients in the age group of 18 to 45 years with complaints of menorrhagia were evaluated. Menstrual blood loss was assessed by pictorial blood loss assessment chart (PBAC). Patients with PBAC score of more than 100, normal pelvic examination, normal cervical cytology were selected for the study.

Exclusion criteria

Patients with irregular menstrual cycles, symptoms of inter menstrual bleeding, spotting were not included for the study. Patients with organic pathology like fibroids, pelvic inflammation, and malignancy were excluded from the study. Also patients with renal impairment, thromboembolic conditions, peptic ulcers and patients on hormone therapy within past three months were excluded from the study.

Patients with complaints of menorrhagia were completely evaluated by a complete medical history, systemic and pelvic examination. Menstrual blood loss was assessed by PBAC in one pre-treatment control cycle. Pretreatment investigations included Hb%, PCV, platelet count, blood group and Rh typing, BT, CT, pelvic ultrasound, PAP smear. Endometrial biopsy was considered in patients aged more than 40 yrs. Any organic pathology detected by pelvic examination, ultrasound, Pap smear and endometrial biopsy were excluded from the study.

54 patients were qualified for the study after meeting inclusion and exclusion criteria. They were allocated to either of the two treatments, mefenamic acid (Group A) or tranexamic acid (Group B) by a computer generated randomization chart (source: www.randomization.com, key10021).

Patients allocated to Group A received mefenamic acid 500 mg TID from day one to day five. Patients allocated to Group B received tranexamic acid 1 gm TID from day one to day five of menstrual cycle for three consecutive cycles. All patients recruited for the study were instructed to use the similar brand and size of sanitary pad available in pharmacy at St. Philomena’s Hospital (trust me, regular size). They were educated about pictorial blood loss assessment chart (score 1 was given for lightly soiled pad, score 5 was given for moderately soiled pad and score 20 for heavily soiled pad, score 1 for 25p coin and score 5 for 1re coin) and were instructed to note the number of pads, staining pattern and the clots as per pictoral blood loss assessment chart. They were instructed to visit outpatient department every month and PBAC scoring was done each month. Symptoms like dysmenorrhoea, any side effects to treatment were enquired. At the end of three treatment cycles, average reduction in PBAC score was calculated. Women with dysmenorrhoea were asked for any improvement or worsening of dysmenorrhoea during the treatment cycles. Hb% was measured at initial visit and at the end of three cycles in the same lab and difference in Hb% was recorded.

Incidence of side effects attributable to the treatment cycles were assessed at each visit and various side effects were recorded.

RESULTS

Of 54 patients recruited for the study, with randomisation, 26 patients were in mefenamic acid (group A) group and 28 patients were in tranexamic acid (group B) group. Four patients were lost for follow up (two in mefenamic acid and two in tranexamic acid group) and did not provide any data. Hence 50 patients were included in the study with an intention to treat and analyse the outcome.

Study design and statistical methods

A comparative study consisting of 50 patients complaining of menorrhagia randomized into two groups- 24 patients in group A (mefenamic acid) and 26 patients in group B (tranexamic acid) was undertaken to know the efficacy, acceptability and safety of two drugs.

Table 1: Age distribution.

<table>
<thead>
<tr>
<th>Age in years</th>
<th>Group A (n=24)</th>
<th>Group B (n=26)</th>
<th>Total (n=50)</th>
</tr>
</thead>
<tbody>
<tr>
<td>18-25</td>
<td>7 (29.17)</td>
<td>8 (30.76)</td>
<td>15 (30.00)</td>
</tr>
<tr>
<td>26-30</td>
<td>8 (33.33)</td>
<td>7 (26.92)</td>
<td>15 (30.00)</td>
</tr>
<tr>
<td>31-35</td>
<td>4 (16.67)</td>
<td>5 (19.23)</td>
<td>9 (18.00)</td>
</tr>
<tr>
<td>36-40</td>
<td>4 (16.67)</td>
<td>5 (19.23)</td>
<td>9 (18.00)</td>
</tr>
<tr>
<td>&gt;40</td>
<td>1 (4.16)</td>
<td>1 (3.84)</td>
<td>2 (4.00)</td>
</tr>
<tr>
<td>Mean±SD</td>
<td>28.67±6.83</td>
<td>29.54±6.38</td>
<td>29.12±6.55</td>
</tr>
<tr>
<td>Inference</td>
<td>Age in years is comparable between two groups with p=0.643</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Chi-square and Fisher test were used to find the significance of homogeneity of samples between group A and group B. Student paired t-test was used to find the
significance of PBAC score and haemoglobin within each group and ANOVA was used to find the significance difference of PBAC scores between group A and group B.

Distribution in age, parity and duration of menorrhagia was comparable between the two groups (Table 1-3).

### Table 2: Parity distribution.

<table>
<thead>
<tr>
<th>Parity</th>
<th>Group A (n=24)</th>
<th>Group B (n=26)</th>
<th>Total (n=50)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nullipara</td>
<td>4 (16.67)</td>
<td>8 (30.76)</td>
<td>12 (24.00)</td>
</tr>
<tr>
<td>Para1</td>
<td>3 (12.50)</td>
<td>5 (19.23)</td>
<td>8 (16.00)</td>
</tr>
<tr>
<td>Para2</td>
<td>10 (41.67)</td>
<td>7 (26.92)</td>
<td>17 (34.00)</td>
</tr>
<tr>
<td>Para3</td>
<td>6 (25.00)</td>
<td>3 (11.54)</td>
<td>9 (18.00)</td>
</tr>
<tr>
<td>Para4 and above</td>
<td>1 (4.17)</td>
<td>3 (11.54)</td>
<td>4 (8.00)</td>
</tr>
</tbody>
</table>

**Inference**
Parity distribution in both the group is comparable with P=0.368

Pretreatment mean PBAC score in group A was 150.67 and in group B was 163.69. Mean PBAC scores in treated cycles in group A during cycle one, two and three were 85.38, 88.46, and 84.42 respectively. When average of three treated cycles were taken mean PBAC score was 104.04 in group A and 82.20 in group B (Table 4).

There was 31% reduction in PBAC score in group A and 50% reduction in group B. Of patients in group B, 23 patients had PBAC score of less than 100 and of group A, 9 patients had PBAC score of less than 100 after treatment. As there was significant difference in mean PBAC score between the two groups in pretreatment cycle, significance was calculated by applying ANOVA keeping the pretreatment scores as covariates. PBAC score was significantly reduced in group B compared to group A with p<0.001(Table 4).

Dysmenorrhoea was present in 11 of 24 patients in group A, 12 of 26 patients in group B. During treatment, improvement in dysmenorrhoea was reported by 9 of 11 patients in group A (81.85%), 8 of 12 patients in group B (61.66%). 2 patients in group A and 4 patients in group B neither had improvement nor worsening. There was no worsening of dysmenorrhoea in either of two groups. Difference in improvement of dysmenorrhoea was not statistically significant between group A and group B (p=0.640).

Side effects were reported by 12 patients in group A and 9 patients in group B. Side effects reported included epigastric pain, nausea, vomiting, and giddiness. When the incidence of side effects were compared between two groups, it was significantly less in group B (p=0.271) (Table 5).

Mean Hb% in pre-treatment cycle was 10.41gm% in group A and 9.88 gm% in group B. At the end of three treatment cycles mean Hb% was 11.35% and 10.70% in group A and group B respectively. Improvement in Hb% was present in 19 patients in group A and 23 patients in group B. Thus Hb% improved significantly in both groups with p value of 0.015 in group A and <0.001 in group B.

**Table 4: Reduction in Menstrual Blood Loss.**

<table>
<thead>
<tr>
<th>PBAC score (Mean± SD)</th>
<th>Group A (n=24)</th>
<th>Group B (n=26)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre treatment cycle</td>
<td>150.67±19.76</td>
<td>163.69±30.28</td>
</tr>
<tr>
<td>Treated cycles</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cycle 1</td>
<td>101.54±25.43</td>
<td>85.38±22.43</td>
</tr>
<tr>
<td>Cycle 2</td>
<td>105.04±18.95</td>
<td>88.46±22.57</td>
</tr>
<tr>
<td>Cycle 3</td>
<td>101.42±29.92</td>
<td>84.42±23.46</td>
</tr>
<tr>
<td>Average of 3 cycles</td>
<td>104.04±17.72</td>
<td>82.20±11.88</td>
</tr>
<tr>
<td>Significance</td>
<td>Student t=14.250, p&lt;0.001</td>
<td>Student t=22.865, p&lt;0.001</td>
</tr>
<tr>
<td>Effect Size</td>
<td>2.48</td>
<td>3.87</td>
</tr>
<tr>
<td>Significance by ANOVA</td>
<td>PBAC score is significantly reduced in group B when compared to group A keeping pre scores as covariates with F=59.647, P&lt;0.001</td>
<td></td>
</tr>
</tbody>
</table>

Mean PBAC score in treated cycles in group B during cycle one, two and three were 85.38, 88.46, and 84.42 respectively.
reduction in blood flow). 3 patients in group B were not willing to continue because of side effects.

There were 2 patients in group A and 4 patients in group B with Intrauterine Contraceptive Devices (IUCD). There was reduction in PBAC score by 47 in group A and by 72 in group B. As sample size of IUCD users was small, no conclusion could be drawn.

DISCUSSION

The present study compares the use of two non-hormonal drugs used in medical management of menorrhagia in terms of reduction of menstrual blood loss, improvement in dysmenorrhea, incidence of adverse effects, improvement in Hb% and improvement of quality of life as reflected by acceptance of treatment.

The present study shows that there is significant reduction in menstrual blood loss both with Tranexamic acid and mefenamic acid, but tranexamic acid proved to be more efficacious. Average mean PBAC scored decreased by 31% in mefenamic acid group and by 50% in tranexamic acid. This was in accordance with previous studies. Cameron et al compared mefenamic acid with norethisterone in 32 patients with ovulatory menorrhagia and found a reduction in menstrual blood loss by 24% in mefenamic acid group and 20% reduction in norethisterone group.6

Peterson et al compared the efficacy of tranexamic acid and norethisterone in management of ovulatory menorrhagia, 25 patients received tranexamic acid, 21 patients received norethisterone.10 They found 45% reduction in menstrual blood loss with tranexamic acid and 20% reduction in menstrual blood loss with norethisterone. Bonnar et al compared efficacy of ethamsylate, mefenamic acid, tranexamic acid for treating menorrhagia in a randomised trial and found reduction in menstrual blood loss by 20% in ethamsylate group, 31% reduction in mefenamic acid group, 54% reduction in tranexamic acid group.11 Lee et al compared the efficacy of tranexamic acid for essential menorrhagia.4

11 patients were with menorrhagia were treated with tranexamic acid 1 gm 6 hourly for 3-4 days (day 1 to day 3) and there was reduction in menstrual blood loss by 54%. Peter et al compared the efficacy of LNG-IUS with mefenamic acid in 51 patients in terms of reduction in menstrual blood loss, PBAC score, total menstrual fluid loss, 25 were randomised to receive LNG-IUS and 26 to receive oral mefenamic acid.3 They found a mean reduction of PBAC score of 37% in mefenamic acid and 95% in LNG-IUS. Most of the previous studies used alkaline haematin method for menstrual blood loss assessment, but this is cumbersome and time consuming procedure and is not available in clinical practice in most set up. Hence a simple but more accurate method of pictorial blood loss assessment chart which has sensitivity and specificity of more than 80% was used in the study. Few of the previous studies do have used pictorial blood loss assessment chart.

In terms of improvement in dysmenorrhea, the present study showed an improvement rate of 88% in Mefenamic acid 66% in tranexamic acid group. Dockery et al12 in comparison of mefenamic acid with danazol in 40 patients with menorrhagia found an improvement rate of 77% in patients treated with mefenamic acid. Bonnar et al13 in comparative study of ethamsylate, tranexamic acid, mefenamic acid show improvement in dysmenorrhea in 4%, 9%, 13% in patients treated with ethamsylate, tranexamic acid and mefenamic acid respectively.

The present study showed a mean increase in Hb% of 9% in mefenamic acid group, and 8.3% in tranexamic acid group. Lee et al reported 7.7% increase in mean Hb% with tranexamic acid for menorrhagia.4 Gleeson et al reported 9.1% increase in mean Hb% I patients who received tranexamic acid for menorrhagia.13

CONCLUSION

Both mefenamic acid and tranexamic acid were effective in management of menorrhagia. Tranexamic acid was superior to mefenamic acid in terms of reduction in menstrual blood loss. Both have the advantage of only being taken during menstruation. Control of dysmenorrhea was achieved in significant number of patients in both groups. Minor side effects like epigastric pain, nausea, vomiting was more frequent in mefenamic acid group. Acceptability rate was high in both groups.

ACKNOWLEDGMENTS

Authors would like to thank Dr Shylaja AS, Dr Chopde SS, Dr Venkatesh N for their support during this study. Authors also acknowledge Mr. K P Suresh for his immense help.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES


Cite this article as: Madhu J, Shylaja AS. Randomised trial of mefenamic acid versus tranexamic acid in management of menorrhagia. Int J Reprod Contracept Obstet Gynecol 2017;6:4608-12.